In a significant development for India's healthcare diagnostics sector, Lords Mark Microbiotech Pvt. Ltd., a part of Lords Mark Industries Limited, has achieved a major quality benchmark. The company has been granted accreditation by the National Accreditation Board for Testing and Calibration Laboratories (NABL). This prestigious recognition establishes the firm as one of the country's most credible and quality-assured diagnostic service providers.
What NABL Accreditation Means for Patients
The NABL accreditation is not just a certificate; it is a powerful validation of the company's unwavering commitment to precision and reliability. This distinction underscores the organisation's high standards in testing accuracy, reporting excellence, and building patient trust. For the everyday Indian, it means the test results they receive from Lords Mark Microbiotech's facilities meet nationally and internationally recognised standards of quality and technical competence.
Speaking on this achievement, Subodh Gupta, CEO of Lords Mark Microbiotech Pvt. Ltd., highlighted its importance. He stated that the accreditation symbolises their steadfast commitment to precision, quality, and trust. Gupta emphasised that it strengthens their mission to make advanced diagnostics and genomic intelligence the cornerstone of preventive healthcare in India.
A Nationwide Expansion Blueprint Unveiled
Building on this quality milestone, the company has unveiled an ambitious growth strategy. Lords Mark Microbiotech plans a massive nationwide expansion to establish 200 advanced laboratories and 2,000 collection centres across India within the next two years. This aggressive scale-up is designed to position the company among the top five organised pathology players in the country.
The expansion will be built upon the existing backbone of 12 advanced laboratories and 68 collection centres. The company's strategy leverages strong instrumentation expertise and a unique, seamless integration of routine pathology with advanced genomic screening under one unified ecosystem. This approach aims to reshape diagnostic access and enable early medical intervention for millions.
Innovating with the Organ Health Score
A key innovation that sets the company apart is its proprietary Organ Health Score. This intelligent health evaluation model moves beyond traditional, episodic diagnosis. It provides personalised, actionable direction for early detection and preventive action, marking a paradigm shift towards continuous and proactive health management. This tool empowers individuals with personalised health insights, aligning with the company's vision for a preventive healthcare future.
Gupta further elaborated that their focus extends beyond mere infrastructure expansion. The core goal is to reshape how Indians access diagnostics, enable early intervention, and empower people with knowledge about their health. He confidently proclaimed that the future of diagnostics is being shaped at Lords Mark Microbiotech.
Accelerating India's Preventive Healthcare Journey
With the NABL validation at its core and a clear, purpose-driven expansion roadmap, Lords Mark Microbiotech is now poised to play a pivotal role in India's healthcare transformation. The company aims to accelerate the nation's transition towards a more accessible, technology-enabled, and preventive healthcare ecosystem. The ultimate vision is a future where proactive disease prevention becomes the standard practice, rather than a rare exception.
This combination of recognised quality, massive scale-up, and patient-centric innovation signals a new chapter for diagnostic services in India. It promises to bring reliable, advanced, and preventive health insights within reach of a broader population.
